Dr. Andrea Apolo’s highlights from ESMO24 – Day 1
24th European Society for Medical Oncology (ESMO) Congress, a major event in the field of oncology. ESMO24 typically features presentations on the latest research, treatment advancements, and clinical practices in oncology.
It gathers experts from around the world to discuss cutting-edge developments in cancer treatment, including new therapies, clinical trials, and advancements in personalized medicine. ESMO 2024 will take place in Barcelona, Spain from 13-17 September this year. In connection to that, Andrea Apolo shared several valuable posts from ESMO24 on her X account:
“Phase 3 study of Tivozanib–Nivo vs Tivo alone in patients with renal cell carcinoma post 1 or 2 prior therapies did not show a benefit DFS, OS, and ORR when adding Nivo. Lower dose of Tivo (0.89 vs 1.34) in the combo arm may have affected outcomes.”
“Final analysis of the phase III LITESPARK-005 study of belzutifan versus everolimus in participants (patients) with previously treated advanced clear cell renal cell carcinoma (ccRCC) showed continued PFS and ORR benefits for beltzutifan.”
“SUNNIFORECAST phase 2 randomised trial of ipilimumab/nivolumab vs standard of care in non-clear cell renal cell cancer show a 12-month OS p=0.014 with no PFS benefit. This was also seen in papillary and chromophobe subgroup analysis.”
“And here are the histologies included in SUNNIFORECAST with Ipi/Nivo. We continue to enroll in the Alliance for Clinical Trials in Oncology ICONIC study of CaboNivoIpi for rare GU tumors includes rare kidney cancer patients.”
“Very interesting new compound, BL-B01D1, an EGFR x HER3 bispecific antibody-drug conjugate (ADC), tested in patients with previously treated metastatic urothelial carcinoma with an ORR 33% (confirmed) across EGFR and HER3 expressions.”
Andrea Apolo is the Chief of the Bladder Cancer Section of the Genitourinary Malignancies Branch and Director of the Bladder Cancer and Genitourinary Tumors Multidisciplinary Clinic at the National Cancer Institute (USA). Apolo received a 2011 National Institutes of Health Award of Merit, the 2014 Lasker Clinical Research Scholars Program Award, the 2018 National Cancer Institute’s Director’s Award for Clinical Science, the 2018 Advancing Cancer Treatment Award for leadership in genitourinary clinical trial patient access, and the 2020 Arthur S. Flemming Award for leaders who make an impact in public service.
Find more updates from ESMO24 on OncoDaily.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023